Cytosolix
Tolland
About Cytosolix
Cytosolix develops novel oral and IV derivatives that target tumor acidity to improve the efficacy of small molecule cancer therapeutics. Cytosolix's Tumor Activated Permeability System, produces weakly-acidic derivatives of known oncology drugs, that enhance the uptake by cancer cells while restricting the uptake by healthy cells, enabling physicians to get safer and more effective therapy for drugs with dose-limiting toxicities.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $6.8M
- Last round: Series Unknown (Jun 2023)
- Website: cytosolix.com
Industries & Categories
Biotechnology, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/cytosolix-460 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.